Danaher Corporation (NYSE:DHR) Shares Sold by AIA Group Ltd

AIA Group Ltd lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 16.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 141,923 shares of the conglomerate’s stock after selling 28,147 shares during the quarter. Danaher comprises about 0.7% of AIA Group Ltd’s investment portfolio, making the stock its 28th biggest position. AIA Group Ltd’s holdings in Danaher were worth $29,094,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Fayez Sarofim & Co lifted its holdings in shares of Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate’s stock valued at $1,902,000 after buying an additional 50 shares during the period. Coastal Bridge Advisors LLC raised its position in Danaher by 4.8% in the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate’s stock worth $252,000 after acquiring an additional 50 shares in the last quarter. MGO One Seven LLC boosted its holdings in Danaher by 1.3% during the fourth quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate’s stock worth $984,000 after buying an additional 53 shares in the last quarter. Hills Bank & Trust Co boosted its stake in shares of Danaher by 0.3% during the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate’s stock worth $3,693,000 after acquiring an additional 53 shares in the last quarter. Finally, Sageworth Trust Co increased its stake in Danaher by 2.3% in the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate’s stock worth $493,000 after purchasing an additional 54 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DHR shares. Argus lowered their target price on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Barclays reissued an “overweight” rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft decreased their target price on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Guggenheim reiterated a “buy” rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $247.61.

Danaher Stock Performance

Shares of NYSE:DHR opened at $200.70 on Monday. The business has a fifty day moving average of $198.46 and a 200-day moving average of $200.62. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a market cap of $143.71 billion, a PE ratio of 42.70, a price-to-earnings-growth ratio of 2.80 and a beta of 0.73. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The firm had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. During the same quarter last year, the business earned $1.72 earnings per share. The company’s revenue was up 3.4% compared to the same quarter last year. On average, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.